SEC Form 4 · accession 0001445064-16-000189
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond J. Furey
Officer — Sr. VP & Chief Compliance Ofcr
Period of report
Jan 2, 2016
Accepted (ET)
Jan 5, 2016 · 5:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 2, 2016 | F | 100 | $74.63 | D | 3,672 | D | |
| Ordinary SharesF1,F2 | Jan 4, 2016 | A | 2,204 | $0.00 | A | 6,237 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F3 | $72.61 | Jan 4, 2016 | A | 14,403 | A | Jan 4, 2017 | Jan 4, 2026 | Ordinary Shares | 14,403 | 14,403 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning January 4, 2017.
- F2Includes 361 shares acquired between January 13, 2015 and December 2, 2015, under the Mallinckrodt employee stock purchase plan.
- F3The options vest in four equal annual installments beginning January 4, 2017.